ACXPAcurx Pharmaceuticals, Inc.同业对比
Acurx Pharmaceuticals, Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACXP本股 | $6M#11 | — | 0.9x#2 | — | — | 43.5%#3 | — | -113.6%#9 | — | — | -85.8%#11 | — |
| AAPG | $7.0B#3 | — | — | — | — | — | — | — | — | — | -54.6%#8 | — |
| AARD | $116M#8 | — | 1.3x#3 | — | — | -179.7%#9 | — | -66.2%#6 | — | — | -58.6%#10 | — |
| ABBV | $436.0B#1 | 121.6x#5 | — | 7.1x#3 | 8.6%#5 | -1.2%#6 | 24.6%#1 | — | 20.0%#1 | — | 30.0%#3 | — |
| ABCL | $2.0B#5 | — | 2.2x#4 | 27.1x#4 | 160.6%#1 | 10.1%#4 | -289.0%#5 | -15.6%#4 | -25.2%#4 | — | 57.3%#1 | — |
| ABEO | $394M#7 | 7.3x#2 | 2.7x#5 | 67.7x#6 | — | -211.7%#10 | -1536.9%#6 | -49.1%#5 | -101.1%#6 | — | 17.9%#4 | — |
| ABT | $164.4B#2 | 26.4x#4 | 3.2x#6 | 3.7x#1 | 5.7%#6 | -51.3%#7 | 18.2%#2 | 12.5%#2 | 8.3%#3 | — | -27.5%#7 | 2.5%#1 |
| ABUS | $938M#6 | 5.7x#1 | 3.6x#8 | 66.6x#5 | 128.2%#2 | 52.1%#2 | -271.0%#4 | -12.9%#3 | — | — | 45.3%#2 | — |
| ABVC | $40M#10 | — | 3.7x#9 | 134.8x#7 | 48.0%#3 | -61.3%#8 | -2416.0%#7 | -73.4%#7 | -65.9%#5 | — | -54.7%#9 | — |
| ACAD | $4.4B#4 | 11.6x#3 | 3.5x#7 | 4.1x#2 | 11.9%#4 | 73.0%#1 | 9.8%#3 | 31.3%#1 | 10.9%#2 | — | 16.6%#5 | — |
| ACET | $82M#9 | — | 0.6x#1 | — | — | 0.3%#5 | — | -83.4%#8 | — | — | -25.2%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议